- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06514456
Italian Validation of the State Urge to be Physically Active- Questionnaire (SUPAQ-I) in Patients With Eating Disorders (SUPAQ-I)
Eating disorders (EDs) are severe psychiatric conditions that cause significant health and psychosocial issues, with Anorexia Nervosa (AN) and Bulimia Nervosa (BN) having the highest mortality rates. The COVID-19 pandemic has led to an increase in ED cases, especially among children, with heightened restrictive eating and compulsive exercise. Up to 80% of individuals with AN engage in compulsive exercise, which current treatments fail to adequately address.
The State Urge to be Physically Active Questionnaire (SUPA-Q) is the only validated tool for assessing activity urges in ED patients, covering cognitive, emotional, and behavioral aspects. This study aims to develop and validate an Italian version of the SUPA-Q (SUPAQ-I) in a clinical sample of ED patients.
A mixed-longitudinal study design will be used, with assessments at admission (T0) and discharge (T1) to evaluate the SUPAQ-I's reliability, validity, and sensitivity to change. The sample will include patients aged 16-65 diagnosed with EDs undergoing inpatient rehabilitation. Statistical analyses will include exploratory and confirmatory factor analyses, and internal consistency will be measured using Cronbach's α and McDonald's Ω indices.
Validating the SUPAQ-I will improve the assessment of activity urges in ED patients, enhancing treatment strategies and outcomes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Margherita Boltri, MSc
- Phone Number: +393405242239
- Email: m.boltri@auxologico.it
Study Locations
-
-
-
Milan, Italy
- Recruiting
- Istituto Auxologico Italiano
-
Contact:
- Leonardo Mendolicchio, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria:
- age between 16 and 65 years old;
- diagnosis of ED as per DSM 5 or DSM-5 TR
- BMI* range between 13 and 30 kg/m2 (depending on ED main diagnosis)
- for the pediatric population BMI SDS** range is set between -3 and +3 SD from expected BMI for age and sex
Exclusion criteria:
- presence of other pathologies not associated with ED (i.e., neurodegenerative diseases);
severe psychopathologies other than ED (i.e., schizophrenia)
- BMI will be calculated using the following formula: weight (kg)/height (m2) **For the pediatric population, BMI SDS will also be calculated to adjust BMI according to growth curve charts for children and adolescents belonging to the Italian population
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Height
Time Frame: through study completion, an average of 24 months
|
height in mt
|
through study completion, an average of 24 months
|
|
Weight
Time Frame: through study completion, an average of 24 months
|
Weight in kg
|
through study completion, an average of 24 months
|
|
BMI
Time Frame: through study completion, an average of 24 months
|
body mass index (in kg/m2)
|
through study completion, an average of 24 months
|
|
State Urge to be Physically Active Questionnaire Italian Version (SUPAQ-I)
Time Frame: through study completion, an average of 24 months
|
State Urge to be Physically Active Questionnaire Italian Version (SUPAQ-I): It consists of a 21-item self-report questionnaire on a 5-point Likert scale (not at all, very little somewhat, quite a bit, a great deal).
Items are divided into four scales (burden, emotional aspects, cognitive aspects and motor aspects).
The higher the score, the greater the restlessness and the "state" urge to be physically active.
Min.
score: 0; max.
score: 84.
A decrease in SUPAQ-I scores means a better outcome.
|
through study completion, an average of 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Eating Disorder Inventory-3 (EDI-3)
Time Frame: through study completion, an average of 24 months
|
The questionnaire consists of 91 items evaluated on a six-point Likert scale (always, usually, often, sometimes, rarely, never).
The 91 items are divided into twelve primary scales (three scales three refer specifically to the eating disorder: drive for thinness (min 7, max 42), bulimia (min 8, max 48), and body dissatisfaction (min 10, max 60); nine general psychological scales relevant but non-specific for eating disorders: low self-esteem (min 6, max 36), personal alienation (min 7, max 42), interpersonal insecurity (min 7, max 42), interpersonal alienation (min 7, max 42), interoceptive deficits (min 9, max 54), emotional dysregulation (min 8, max 48), perfectionism (min 6, max 36), asceticism (min 7, max 42), and maturity fears (min 8, max 48).
The higher the score, the greater the severity of the symptoms.
A decrease in EDI-3 scores means a better outcome.
|
through study completion, an average of 24 months
|
|
Compulsive Exercise Test (CET)
Time Frame: through study completion, an average of 24 months
|
The CET consists of a 24-item self-administered questionnaire evaluated on a 6-point Likert scale from 0 (never true) to 5 (always true).
Items are divided into four scales (avoidance, weight control, mood, lack of enjoyment and rigidity).
The Italian version of the CET showed acceptable reliability (Cronbach's α coefficients for all the domains > .70).
The higher the score, the greater the "trait"-like compulsive physical activity (cut-off is set at 15 points).
Min score: 0; max.
score: 120.
A decrease in CET scores means a better outcome.
|
through study completion, an average of 24 months
|
|
Exercise Addiction Inventory - Revised (EAI-R)
Time Frame: through study completion, an average of 24 months
|
Exercise Addiction Inventory - Revised : The EAI-R consists of a 6-item self-report questionnaire evaluated on a 6-point Likert scale from 1 (strongly disagree) to 6 (strongly agree).
The higher the score the strongest the exercise addiction risk.
Min score: 6; max score: 36.
A decrease in EAI-R scores means a better outcome.
|
through study completion, an average of 24 months
|
|
Barratt Impulsiveness Scale (15 item) (BIS-15)
Time Frame: through study completion, an average of 24 months
|
Barratt Impulsiveness Scale (15 item): It consists of a 15-item self-report questionnaire evaluated on a 4-point Likert scale from 1 (rarely/never) to 4 (almost always/always).
Items are divided into four scales (pure impulsivity, planning and thinking, lack of attention and concentration impulsive buying).
The higher the total score, the greater impulsivity.
Min score: 15; max score: 60.
This questionnaire will be used to test for divergent validity of the SUPAQ-I.
|
through study completion, an average of 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Age
Time Frame: through study completion, an average of 24 months
|
age in years
|
through study completion, an average of 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Leonardo Mendolicchio, M.D., IRCCS Istituto Auxologico Italiano
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 49C402
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Feeding and Eating Disorders
-
Region of Southern DenmarkUniversity of Southern Denmark; JaschaFondenNot yet recruitingOther Specified Feeding or Eating Disorder | Eating Disorder NosDenmark
-
Benny Kerzner, MDAbbott NutritionWithdrawnFeeding and Eating Disorders of Childhood | Feeding DifficultiesUnited States
-
Meyer Children's Hospital IRCCSActive, not recruitingFeeding and Eating Disorders of ChildhoodItaly
-
Universidad Francisco de VitoriaDavid Varillas Delgado; María Cristina Martincrespo-Blanco; Saray Blanco-Abril; María Gema Cid-Expósito and other collaboratorsCompleted
-
Federal University of Health Science of Porto AlegreMinistry of Health, Brazil; Fundação de Amparo à Pesquisa do Estado do Rio...CompletedFeeding and Eating Disorders of ChildhoodBrazil
-
University of Sao Paulo General HospitalActive, not recruitingBinge Eating DisorderBrazil
-
Emory UniversityCompletedFeeding and Eating Disorders of ChildhoodUnited States
-
Kelly TannerCompleted
-
University of OregonActive, not recruitingDepression | Parent-Child Relations | Disordered Eating Behaviors | Feeding BehaviorsUnited States
-
Children's Mercy Hospital Kansas CityThe Gerber FoundationEnrolling by invitationFeeding and Eating Disorders of Childhood | Gastrostomy | Feeding Disorder of Infancy and ChildhoodUnited States
Clinical Trials on no intervention
-
Hopital FochNot yet recruitingInterstitial Lung DiseaseFrance
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Huashan HospitalZhejiang Cancer Hospital; Shanghai Zhongshan Hospital; Tongji Hospital; Qilu Hospital... and other collaboratorsRecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in VitroChina
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown